Study Results Support the use of TellDx to Personalize Cancer Care Management –-- Clinical study published in Cancer Discovery --ANDOVER, ...
The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...
The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...
Digesting the new dietary guidelines, a "wipe test" for PFAS on firefighter gear, a potential new path for small-cell lung ...
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to ...
Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback